Why Stem Cell Dosage Matters

A growing body of research now supports what we see in our clinic every day: more isn’t just more—it’s better when it comes to stem cell dosing.

In many U.S.-based trials, injections using only 5–10 million cells have failed to show statistical benefit over cortisone injections. One recent high-profile example is a 2023 study published in Nature Medicine:

“At one year post-injection, none of the three orthobiologic injections was superior to CSI control.”
— Mautner et al., Nature Medicine, 2023

This study compared low-dose injections of bone marrow concentrate, umbilical cord MSCs, and adipose-derived cells to corticosteroids. But crucially, cell counts were too low—typically 5 to 10 million—and viability wasn’t emphasized. These design limitations, as Dr. Yi Song points out, may explain why the stem cell therapies underperformed.

Clinical Experience: 50 Million Cells Last Longer

In contrast, our clinic uses lab-expanded umbilical cord MSCs with verified 85–94% viability—a level rarely matched by frozen, non-manipulated cells used in many U.S. clinics.

Patients who receive a single injection of 50 million cells into joints like the knee or shoulder often report:

• Significant pain reduction
• Improved mobility
• Results lasting 2–3 years or more without repeat injections

Supporting Study: Zhao et al. (2019)

A 2019 study by Zhao et al., published in Stem Cell Research & Therapy, evaluated the efficacy of intra-articular injections of 10 million, 20 million, and 50 million allogeneic adipose-derived mesenchymal stem cells (MSCs) for treating knee osteoarthritis. Patients received a single injection, and outcomes were measured using MRI imaging and clinical scoring systems like WOMAC and VAS.

• Dose-dependent improvement in cartilage quality was observed, particularly in the 50 million cell group.
• No serious adverse effects were reported, and higher doses were well tolerated.
• MRI showed significantly better cartilage repair in the 50M group compared to 10M and 20M.